ArticleFrontiers in pharmacology2023
Article in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Phytotherapy for acute respiratory tract infections in children: a systematically conducted, comprehensive review.Frontiers in pediatrics · 2025Pooled it
- Taxifolin Regulates the Gene Expression of MUC5AC Mucin via Affecting IκBα/NF-κB p65 Signaling in Human Airway Epithelial Cells.Biomolecules & therapeutics · 2025Article
- Efficacy and Safety of YJP-40 in Patients with Acute Bronchitis: A Randomized, Double-Blind, Parallel Group Study.Tuberculosis and respiratory diseases · 2025Article
- Prescription of EPs 7630 is associated with short- and long-term benefits in acute bronchitis: a real-world data analysis.Frontiers in pharmacology · 2025Article
- Unlocking the therapeutic potential ofHeliyon · 2024Article
- Multiple mechanisms enable broad-spectrum activity of theFrontiers in pharmacology · 2024Review
- Long-term benefits of EPsFrontiers in pharmacology · 2024Article
- Identifying in-market application of Pelargonium root extract EPs 7630 for the treatment of COVID-19: analysis of pharmacovigilance data.Frontiers in pharmacology · 2024Article
- Stevens' Cure (Umckaloabo)-the vindication of a patent medicine.Frontiers in pharmacology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The occurrence of immune-evasive SARS-CoV-2 strains emphasizes the importance to search for broad-acting antiviral compounds. Our previous
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.